Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Therapy for Recurrent Glioblastoma
NCT03681028Phase 1Completed
- Start
- Dec 2018
- Primary completion
- Nov 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in glioblastoma (GBM). Primary endpoints: Percentage of patients who have successfully initiated therapy at 35 days and Overall Survival at 9 months. Started Dec 2018; status: completed.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03681028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03681028.